CytomX Therapeutics (CTMX) financial statements
CytomX Therapeutics reported revenue of $76M in fiscal 2025, up 21.9% a year over 9 years.
Net income was -$17M and the operating margin -29.3%, against -463.9% in 2016.
Free cash flow was -$76M.
The diluted share count rose 281% over the period (dilution).
Revenue and free cash flow
Fiscal years, $ billions.
Income statement
Fiscal years, from CytomX Therapeutics's 10-K filings with the SEC.
| Fiscal year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $13M | $72M | $60M | $27M | $68M | $37M | $53M | $101M | $138M | $76M |
| Research and development | $55M | $92M | $104M | $132M | $113M | $114M | $112M | $78M | $83M | $69M |
| Selling, general and admin | $20M | $26M | $34M | $37M | $36M | $39M | $43M | $30M | $30M | $30M |
| Operating income | -$60M | -$46M | -$78M | -$141M | -$81M | -$116M | -$101M | -$6M | $25M | -$22M |
| Interest expense | $2M | — | — | — | — | — | — | — | — | — |
| Pre-tax income | -$59M | -$44M | -$70M | -$133M | -$79M | -$116M | -$99M | $3M | $32M | -$17M |
| Income tax | -$19,000 | -$513,000 | $14M | -$427,000 | -$14M | $0 | $0 | $4M | $224,000 | $238,000 |
| Net income | -$59M | -$43M | -$85M | -$133M | -$65M | -$116M | -$99M | -$569,000 | $32M | -$17M |
| EPS (diluted) | -$1.63 | -$1.16 | — | — | — | — | — | — | — | — |
| Diluted shares | 36M | 37M | 42M | 45M | 46M | 64M | 66M | 74M | 85M | 138M |
| Operating margin | -463.9% | -64.6% | -130.9% | -525.9% | -117.7% | -311.0% | -190.6% | -6.4% | 18.1% | -29.3% |
| Net margin | -458.5% | -60.2% | -142.2% | -493.7% | -94.7% | -310.5% | -186.8% | -0.6% | 23.1% | -22.8% |
Balance sheet
Fiscal years, from CytomX Therapeutics's 10-K filings with the SEC.
| Fiscal year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and short-term investments | $182M | $374M | $436M | $279M | $256M | $266M | $96M | $175M | $102M | $137M |
| Receivables | $2M | $10M | $97,000 | $13,000 | $798,000 | $790,000 | $36M | $3M | $3M | $2M |
| Total current assets | $188M | $389M | $445M | $303M | $324M | $310M | $237M | $183M | $107M | $144M |
| Property, plant and equipment | $4M | $4M | $7M | $7M | $7M | $6M | $5M | $4M | $2M | $1M |
| Goodwill | $949,000 | $949,000 | $949,000 | $949,000 | $949,000 | $949,000 | $949,000 | $949,000 | $949,000 | $949,000 |
| Total assets | $199M | $398M | $457M | $341M | $359M | $339M | $261M | $202M | $121M | $152M |
| Total current liabilities | $36M | $61M | $98M | $86M | $68M | $78M | $153M | $156M | $86M | $47M |
| Total liabilities | $121M | $328M | $326M | $290M | $366M | $340M | $347M | $249M | $121M | $53M |
| Shareholders' equity | $78M | $70M | $136M | $25M | -$8M | -$459,000 | -$86M | -$47M | -$456,000 | $99M |
| Net debt | -$105M | -$178M | -$248M | -$188M | -$192M | -$206M | -$194M | -$17M | -$38M | -$13M |
Cash flow
Fiscal years, from CytomX Therapeutics's 10-K filings with the SEC.
| Fiscal year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$2M | $170M | -$76M | -$140M | $5M | -$119M | -$111M | -$56M | -$86M | -$76M |
| Capital spending | $2M | $2M | $4M | $3M | $2M | $2M | $2M | $840,000 | $310,000 | $220,000 |
| Free cash flow | -$4M | $169M | -$79M | -$144M | $3M | -$121M | -$113M | -$57M | -$87M | -$76M |
| Stock-based compensation | $10M | $11M | $17M | $19M | $15M | $13M | $13M | $9M | $8M | $6M |
| Free cash flow margin | -32.8% | 235.7% | -133.3% | -535.2% | 4.3% | -323.3% | -211.7% | -56.2% | -62.7% | -99.5% |
Every line, every quarterThe deep dive has fifteen-plus years of statements, quarterly results, charts and valuation models for CTMX.
Open CTMX in InvestinglyQuestions
What was CytomX Therapeutics's revenue in 2025?
$76M in fiscal 2025, from its 10-K filing.
How much free cash flow does CytomX Therapeutics generate?
-$76M in fiscal 2025 (operating cash flow minus capital spending).
From CytomX Therapeutics's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.